Cosmos Health Enters US Market with DolCas Biotech Manufacturing Pact.

Cosmos Health, a global healthcare group, has entered the US market and launched US-based manufacturing through a strategic agreement with DolCas Biotech. The move aims to mitigate tariff exposure and logistical risks, while enhancing production control beyond its existing European footprint. Cosmos Health will commence production at GMP-certified facilities, marking a significant milestone in its operational expansion.

Cosmos Health Inc. (NASDAQ:COSM), a diversified global healthcare group, has announced its entry into the U.S. market with a strategic manufacturing agreement with DolCas Biotech LLC. This move aims to mitigate tariff exposure and logistical risks while enhancing production control beyond its existing European footprint. The company will commence production at Good Manufacturing Practice (GMP)-certified facilities in the United States, marking a significant milestone in its operational expansion.

The partnership with DolCas Biotech, a New Jersey-based nutraceutical manufacturer, will leverage the latter's expertise in clinically validated formulations and vertically integrated manufacturing. This collaboration strengthens Cosmos Health's position in the premium nutraceuticals space and supports its broader strategy to expand its portfolio with scientifically backed, high-efficacy ingredients.

Cosmos Health's entry into the U.S. market addresses a critical market access gap in its global portfolio. The U.S. represents the world's largest nutraceutical market, with distinctive regulatory, competitive, and consumer preference characteristics that differ significantly from European markets. This move is expected to provide several competitive advantages, including local manufacturing credentials that resonate with U.S. consumers, access to clinically validated formulations, and vertically integrated production for better quality control and potential cost efficiencies.

The strategic agreement with DolCas Biotech also provides Cosmos Health with access to established GMP-certified infrastructure without the capital expenditure of building new facilities. This capital-efficient approach to manufacturing expansion allows for faster market entry while preserving financial flexibility.

The partnership's potential for accelerated product development suggests that Cosmos Health could rapidly expand its U.S. product portfolio with innovations tailored to American consumer preferences and regulatory requirements. This could create additional revenue streams beyond its existing product lineup.

Cosmos Health's CEO, Greg Siokas, stated, "We are proud to reach this important milestone as we commence production in the United States through our agreement with DolCas Biotech, a partner widely recognized for its commitment to quality and innovation. This strategic move strengthens our supply chain, enhances production oversight, and positions Cosmos for scalable global growth. It also reduces exposure to tariff-related risks, adding resilience amid shifting trade dynamics."

DolCas Biotech's CEO, K. Gnaneshwar Rao, expressed enthusiasm for the collaboration, stating, "We are thrilled to partner with Cosmos and are eager to build on this collaboration with a wide range of innovative products that will benefit both companies. Cosmos, under the visionary leadership of CEO Greg Siokas, has built an impressive portfolio of brands and products. His forward-thinking approach aligns perfectly with our values and ambitions. We see this as the beginning of a strong, strategic partnership and look forward to supporting Cosmos’ continued growth in the United States and globally."

References:
[1] https://www.stocktitan.net/news/COSM/cosmos-health-enters-u-s-market-with-strategic-made-in-america-4qbfaa7hoena.html
[2] https://www.globenewswire.com/news-release/2025/06/24/3104454/0/en/Cosmos-Health-Enters-U-S-Market-with-Strategic-Made-in-America-Manufacturing-Mitigating-Tariff-Risks-Executes-Agreement-with-New-Jersey-Based-DolCas-Biotech.html